Roivant Sciences Ltd.

Pharmaceutical Preparations·LONDON·FY end 03/31·CIK 1635088

Named Executive Officers

FY 2024

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Mayukh SukhatmePresident and Chief Investment Officer	$550.0K	$170.2M	—	$81.1M	$21.0K	$251.9M
Matthew GlineChief Executive Officer	$725.0K	$157.6M	—	$5.0M	$12.0K	$163.3M
Eric VenkerPresident and Immunovant CEO	$600.2K	$2.2M	$2.9M	$6.0M	$32.7K	$11.8M
Rakhi KumarFormer Chief Accounting Officer	$370.2K	$412.4K	$1.9M	$1.7M	$398.2K	$4.7M
Richard PulikChief Financial Officer	$437.8K	$410.1K	$2.2M	$1.1M	$1.8K	$4.1M
Jennifer HumesChief Accounting Officer	$41.9K	$1.2M	$826.9K	$281.4K	$1.3K	$2.4M

Matthew Gline · FY 2024

Stock awards$157.6M96%

Performance bonus$5.0M3%

Salary$725.0K0%

Other$12.0K0%

TSR % vs. CEO comp actually paid · 3 fiscal years · Item 402(v) disclosure

TSR

CEO comp

FY22

+49%

$98M

FY23

+113%

$46M

FY24

+104%

$120M

Need at least two fiscal years of proxy data to draw the trend line. The ingestion worker will populate prior-year proxies as it processes them.